Adenoid Cystic Carcinoma Market

Key Highlights

 

• According to Calderón Boyle et al. (2020) in the US, Adenoid Cystic Carcinoma incidence rate was 0.35 per 100,000. Adenoid Cystic Carcinoma limited duration prevalence was highest in those aged 75-79 years and in females, and lowest among Native Americans/Alaska Natives. Adenoid Cystic Carcinoma cases were highest in the oral cavity and pharynx.

 

• A multicenter Baujat et al. (2020), the across Europe average age for Adenoid Cystic Carcinoma was 55 years and females accounted for 59.4% of the cohort. The body mass index (BMI) was normal in 86% of cases while tumor was located in minor salivary glands in 60% of cases. T3/T4 stages represented 58%; 89% of patients and histological grade III was observed on 21% of patients. The EFS and overall 5-year survival rates were 50% and 85%, respectively. 

 

• According to Inagaki et al. (2020) study of Adenoid Cystic Carcinoma cases of salivary gland origin in Japan, 5-year overall survival (OS) and disease-free survival (DFS) rates were 92.5% and 50.0%, respectively with treatment failure in 46% cases while distant failures in 34%.

 

• Adenoid Cystic Carcinoma Market Companies are working in the market such as Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co, and others.

 

• Adenoid Cystic Carcinoma epidemiology is segmented as Total Adenoid Cystic Carcinoma Incident Cases, Adenoid Cystic Carcinoma Gender-specific Cases, Adenoid Cystic Carcinoma Grade-specific Cases, and Adenoid Cystic Carcinoma Treatable Cases in the Adenoid Cystic Carcinoma market report.

 

Request a sample to unlock the CAGR for  Adenoid Cystic Carcinoma Market

 

Factors affecting Adenoid Cystic Carcinoma Market Growth

 

• Rising Incidence of Salivary Gland and Head & Neck Cancers

Growing cases of ACC increase demand for effective treatment options.

• Limited Effective Treatment Options

High unmet medical need for targeted therapies and improved outcomes fuels market growth.

• Advancements in Diagnostic Technologies

Improved imaging, biopsy techniques, and molecular profiling support early and accurate diagnosis.

• Emergence of Targeted Therapies and Immunotherapies

Development of novel drugs and biologics enhances treatment efficacy and patient outcomes.

• Expansion of Oncology Healthcare Infrastructure

Increasing availability of specialized cancer centers improves patient access to care.

• Government and NGO Initiatives

Cancer awareness programs, funding for rare cancer research, and early screening campaigns drive diagnosis and treatment uptake.

• Growing Awareness and Early Detection

Patient education and physician training programs encourage timely intervention.

• Technological Innovations in Drug Delivery

Targeted delivery systems and combination therapies improve safety and efficacy.

• Strategic Collaborations & Clinical Research

Partnerships between pharmaceutical companies, research institutes, and hospitals accelerate drug development.

• Patient Advocacy & Support Programs

Rare cancer awareness groups encourage clinical trial participation and treatment adherence.

 

DelveInsight's "Adenoid Cystic Carcinoma Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Adenoid Cystic Carcinoma, historical and forecasted epidemiology as well as the Adenoid Cystic Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Adenoid Cystic Carcinoma market report provides current treatment practices, emerging drugs, Adenoid Cystic Carcinoma market share of the individual therapies, current and forecasted Adenoid Cystic Carcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Adenoid Cystic Carcinoma treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

 

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

Study Period: 2019–2032

 

Adenoid Cystic Carcinoma Market Disease Understanding 

The DelveInsight’s Adenoid Cystic Carcinoma market report gives a thorough understanding of Adenoid Cystic Carcinoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma that begins in the glandular tissues. It commonly develops in the salivary glands or other regions of the head and neck but can also occur in other parts of the body, such as the breast, skin, cervix in females, prostate gland in males, etc. Adenoid cystic carcinoma tumors are characterized by a distinctive histological pattern of abnormal “nests” or cords of epithelial cells that surround or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes, apparent during the microscopic evaluation of tumor cells.

 

Signs & symptoms depend largely on the site of origin of the tumor. Early lesions of the salivary glands are present as painless masses of the mouth or face, usually growing slowly. Advanced tumors result in pain and nerve paralysis. Tumors of the lacrimal gland present as proptosis and changes in vision while Adenoid Cystic Carcinoma arising in the tracheobronchial tree may have respiratory symptoms, and those in the larynx may lead to changes in speech.

 

Adenoid Cystic Carcinoma Diagnosis

The diagnosis is made by histological analysis of a biopsy or specimen of a tumor mass. There are no serum markers for this neoplasm. Recurrences are usually identified by radiographic imaging techniques, such as computed tomography, MRI, and PET scan. There are three tumor growth patterns common to Adenoid Cystic Carcinoma: cribriform, tubular, and solid. Cribriform is most common while cribriform and tubular both are less aggressive. The WHO has classified Adenoid cystic carcinoma into Grade I, II and III based on these forms.

 

The exact cause of adenoid cystic carcinoma is unknown. Researchers speculate that a protein produced by MYB-NFIB plays a role in the development of Adenoid Cystic Carcinoma tumors. There is a slight female preponderance and it is staged using the TNM system for salivary gland tumors.

 

Adenoid Cystic Carcinoma Treatment

Surgical resection is the mainstay therapy followed by postoperative radiotherapy. Neutron beam therapy may be more effective than conventional radiation to help limit local failure. Adenoid Cystic Carcinoma is resistant to chemotherapy although some may receive palliation.  However several clinical trials are examining the effects of relatively new chemotherapeutic drugs (paclitaxel, gemcitabine, etc.) alone, or combination of drugs, in the control of metastatic or locally recurrent ACC and will impact the market in future.

 

Adenoid Cystic Carcinoma is a low-grade malignancy with slow growth. It is rarely invasive and infiltrates nearby lymph nodes and perineural spaces but it has a tendency for local recurrence and in approximately half of the patients it spreads to distant bodily sites, particularly the lungs resulting in life-threatening complications. Unlike most carcinomas, most of the Adenoid Cystic Carcinoma patients survive for 5 years, only to have tumors recur and progress.

 

Adenoid Cystic Carcinoma Epidemiology Analysis

The Adenoid Cystic Carcinoma epidemiology section provides insights about historical and current Adenoid Cystic Carcinoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings from Adenoid Cystic Carcinoma Epidemiological Analyses and Forecast

 

• According to Calderón Boyle et al. (2020) in the US, Adenoid Cystic Carcinoma incidence rate was 0.35 per 100,000. Adenoid Cystic Carcinoma limited duration prevalence was highest in those aged 75-79 years and in females, and lowest among Native Americans/Alaska Natives. Adenoid Cystic Carcinoma cases were highest in the oral cavity and pharynx.

 

• A multicenter Baujat et al. (2020), the across Europe average age for Adenoid Cystic Carcinoma was 55 years and females accounted for 59.4% of the cohort. The body mass index (BMI) was normal in 86% of cases while tumor was located in minor salivary glands in 60% of cases. T3/T4 stages represented 58%; 89% of patients and histological grade III was observed on 21% of patients. The EFS and overall 5-year survival rates were 50% and 85%, respectively. 

 

• According to Inagaki et al. (2020) study of Adenoid Cystic Carcinoma cases of salivary gland origin in Japan, 5-year overall survival (OS) and disease-free survival (DFS) rates were 92.5% and 50.0%, respectively with treatment failure in 46% cases while distant failures in 34%.

 

• The disease epidemiology covered in the report provides historical as well as forecasted Adenoid Cystic Carcinoma epidemiology [segmented as Total Incident Cases of Adenoid Cystic Carcinoma, Gender-specific Cases of Adenoid Cystic Carcinoma, Grade-specific Cases of Adenoid Cystic Carcinoma, and Treatable Cases of Adenoid Cystic Carcinoma] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

 

Country-Wise- Adenoid Cystic Carcinoma Epidemiology

This section provides a glimpse of the Adenoid Cystic Carcinoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

Learn more about the evolving epidemiology trends and key developments: Adenoid Cystic Carcinoma Epidemiology Forecast
 

Adenoid Cystic Carcinoma: Recent Developments

• In September 2025, Rgenta Therapeutics received FDA Orphan Drug Designation for RGT-61159, an oral small molecule targeting MYB via RNA splicing modulation, for the treatment of adenoid cystic carcinoma (ACC). The drug is currently in a Phase 1a/b trial for relapsed/refractory ACC and colorectal cancer.

Adenoid Cystic Carcinoma Drug Analysis

The drug chapter segment of the Adenoid Cystic Carcinoma report encloses the detailed analysis of Adenoid Cystic Carcinoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Adenoid Cystic Carcinoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Adenoid Cystic Carcinoma Marketed Drugs

Note: Detailed Current therapies assessment will be provided in the full report of Adenoid Cystic Carcinoma 

 

Adenoid Cystic Carcinoma Emerging Drugs

 

• lenvatinib and pembrolizumab are being investigated by Merck in advanced Adenoid Cystic Carcinoma patients and other salivary gland cancers that have recurred or spread to other parts of the body.

 

• AL101 being developed by Ayala Pharmaceuticals is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). The FDA granted Orphan Drug Designation (ODD) and Fast Track Designation (FTD) to AL101 for the potential treatment of Adenoid Cystic Carcinoma.

 

Note: Detailed emerging therapies assessment will be provided in the full report of Adenoid Cystic Carcinoma

 

Adenoid Cystic Carcinoma Market Outlook

Surgical resection, is the mainstay therapy though there may be some associated complications that vary depending upon the surgical site like surgery of the parotid salivary gland may damage facial nerves, which can cause the muscles in the face to droop. Based on Adenoid Cystic Carcinoma clinical trial experience, many also advocate for postoperative radiotherapy as an adjuvant therapy to help limit local failure. Occasionally, it is not possible to remove Adenoid Cystic Carcinoma using surgery. 

 

If initial surgery is not an option due to the specific location or progression of the malignancy, radiation therapy may be done. Type of radiation used, depends upon the cancer type, location, stage and grade, prior treatments, etc. Thermal ablation is also a frequently used alternative for patients dealing with metastases.

 

Systemic therapies do not have much presence in the therapeutic landscape of Adenoid Cystic Carcinoma, since this does not show significant response to chemotherapy, which is though at times, used as a palliative measure. The other form of systemic therapy, i.e. targeted therapy, is still yet to be considered a prominent alternative, since they still remain developmental phases. Although targeted therapy drugs like tyrosine kinase inhibitors (TKIs) — lenvatinib or sorafenib — have shown good efficacy, they still require further, wider studies to prove it.

 

The dynamics of the Adenoid Cystic Carcinoma market is anticipated to change in the coming years owing to the rising awareness of Adenoid Cystic Carcinoma, and improvement in the research and development undertaking. Some of the key Adenoid Cystic Carcinoma companies in the market include Merck, Ayala Pharmaceuticals and others are involved in developing therapies for Adenoid Cystic Carcinoma.

 

According to DelveInsight, the Adenoid Cystic Carcinoma market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Analyst Commentary

• The pipeline of Adenoid Cystic Carcinoma is very robust, many potential therapies are being investigated for the treatment of Adenoid Cystic Carcinoma, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

 

• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Adenoid Cystic Carcinoma market in the 7MM. Aside from that, the market size of Adenoid Cystic Carcinoma may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.

 

• The market growth of Adenoid Cystic Carcinoma may be offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

 

Adenoid Cystic Carcinoma Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Adenoid Cystic Carcinoma market or expected to get launched in the market during the study period 2019-2032. The analysis covers Adenoid Cystic Carcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. 

 

Note: Detailed emerging therapies assessment will be provided in the full report of Adenoid Cystic Carcinoma.

 

 Adenoid Cystic Carcinoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes Adenoid Cystic Carcinoma companies involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Adenoid Cystic Carcinoma emerging therapies.

 

Learn more about the emerging therapies and key companies active in the therapeutics segment: Adenoid Cystic Carcinoma Pipeline Insight
 

Adenoid Cystic Carcinoma Market Access and Reimbursement

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

Latest KOL Views on Adenoid Cystic Carcinoma

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Adenoid Cystic Carcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Adenoid Cystic Carcinoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the Adenoid Cystic Carcinoma unmet needs.

 

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Adenoid Cystic Carcinoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Report Metrics	Details
Study Period	2019 to 2032
Forecast Period	2023 to 2032
Market CAGR	Request Sample to Know
Adenoid Cystic Carcinoma Market Size	USD XX million by 2032
Key Adenoid Cystic Carcinoma Companies	Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co and others.

 

Scope of the Adenoid Cystic Carcinoma Market Report

• The report covers the descriptive overview of Adenoid Cystic Carcinoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Adenoid Cystic Carcinoma epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Adenoid Cystic Carcinoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Adenoid Cystic Carcinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the global Adenoid Cystic Carcinoma market

 

Adenoid Cystic Carcinoma Market Report Highlights

• In the coming years, the Adenoid Cystic Carcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Adenoid Cystic Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Several major Adenoid Cystic Carcinoma companies are involved in developing therapies to improve the treatment scenario. The launch of emerging therapies will significantly impact the Adenoid Cystic Carcinoma market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Adenoid Cystic Carcinoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed  Adenoid Cystic Carcinoma clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Adenoid Cystic Carcinoma Report Insights

• Patient Based Market Forecasting
• Therapeutic Approaches
• Adenoid Cystic Carcinoma Pipeline Analysis
• Adenoid Cystic Carcinoma Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

 

Adenoid Cystic Carcinoma Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Adenoid Cystic Carcinoma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Adenoid Cystic Carcinoma Drugs Uptake

 

Adenoid Cystic Carcinoma Report Assessment

• Current Treatment Practices
• Adenoid Cystic Carcinoma Unmet Needs
• Adenoid Cystic Carcinoma Pipeline Product Profiles
• Adenoid Cystic Carcinoma Market Attractiveness

 

Key Questions Answered in the Adenoid Cystic Carcinoma Report

 

Market Insights:

• What was the Adenoid Cystic Carcinoma drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Adenoid Cystic Carcinoma total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest Adenoid Cystic Carcinoma market size during the forecast period (2019-2032)?
• At what CAGR, the Adenoid Cystic Carcinoma market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Adenoid Cystic Carcinoma market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Adenoid Cystic Carcinoma market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Adenoid Cystic Carcinoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Adenoid Cystic Carcinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Adenoid Cystic Carcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the Adenoid Cystic Carcinoma population?
• Out of all 7MM countries, which country would have the highest incident population of Adenoid Cystic Carcinoma during the forecast period (2019-2032)?
• At what CAGR the patient Adenoid Cystic Carcinoma population is expected to grow by 7MM during the forecast period (2019-2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Adenoid Cystic Carcinoma Therapies:

• What are the current options for the Adenoid Cystic Carcinoma treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Adenoid Cystic Carcinoma in the USA, Europe, and Japan?
• What are the Adenoid Cystic Carcinoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Adenoid Cystic Carcinoma?
• How many therapies are in-development by each company for Adenoid Cystic Carcinoma treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Adenoid Cystic Carcinoma treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Adenoid Cystic Carcinoma therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the major ongoing Adenoid Cystic Carcinoma clinical trial studies and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Adenoid Cystic Carcinoma?
• What are the global historical and forecasted markets of Adenoid Cystic Carcinoma?

 

Reasons to buy Adenoid Cystic Carcinoma Report

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Adenoid Cystic Carcinoma market
• Organize sales and marketing efforts by identifying the best opportunities for Adenoid Cystic Carcinoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Adenoid Cystic Carcinoma market
• To understand the future market competition in the Adenoid Cystic Carcinoma market